Treatment of Friedreich Ataxia with Restless Legs Syndrome
Clinical Scenario
This protocol addresses individuals with Friedreich ataxia who have a co-occurring restless legs syndrome (RLS), with or without associated periodic limb movements in sleep (PLMS).
Comorbidity Considerations
In Friedreich ataxia, the presence of restless legs syndrome — with or without periodic limb movements in sleep — warrants a structured management approach. Prevention strategies and lifestyle changes are conditionally recommended alongside pharmacological options for those whose RLS interferes with sleep.
Treatment Approach (Partial Overview)
When RLS interferes with sleep in this population, evidence-based pharmacological treatment is recommended. Certain preferred medication classes are indicated, while others require caution due to specific risks in this setting.
The full regimen — including drug selection, sequencing, and conditions for additional interventions — is available in the complete structured protocol.
References
DOI: 10.1186/s13023-022-02568-3
- We conditionally recommend the use of prevention strategies/lifestyle changes (such as reduction of alcohol and nicotine use) over no prevention strategies/lifestyle changes or medication in individuals with Friedreich ataxia with restless legs syndrome.
- We conditionally recommend medication for individuals with Friedreich ataxia with RLS which interferes with sleep (with or without associated PLMS) over no medication.
- Gabapentin and pregabalin are the preferred choice of pharmacological treatment of RLS in Friedreich ataxia as they are as effective as levodopa but do not have the same side-effects.
- The dopamine agonists pramipexole and ropinirole may be helpful but should be used with caution in Friedreich ataxia due to the risk of augmentation of RLS symptoms.
- Levodopa may be used intermittently when disabling RLS/PLMS symptoms are present since augmentation of RLS occurs only with long-term use.
- We suggest iron supplementation could be trialed for treatment of RLS in individuals with Friedreich ataxia and serum ferritin < 50 mcg/ml, but only if other treatments have been tried and are not effective.
View source ↗